Drug Profile
Selitrectinib - Bayer
Alternative Names: BAY-2731954; LOXO 195; Tyrosine receptor kinase inhibitor - BayerLatest Information Update: 22 Jan 2024
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Bayer
- Class Antineoplastics; Pyrazoles; Pyridines; Pyrrolidinones; Small molecules
- Mechanism of Action Tropomyosin-related kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Jan 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics) (AACR-NCI-EORTC-2023)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In the elderly, In infants, Late-stage disease, Second-line therapy or greater, In adults) in Australia (PO, Capsule)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(In adolescents, In children, In the elderly, In infants, Late-stage disease, Second-line therapy or greater, In adults) in Australia (PO, Liquid)